Press Release: PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results

Dow Jones11-11

D-PLEX NDA Under FDA Priority Review with PDUFA Goal Date of November 28, 2026; U.S. Commercial Launch Preparations Ongoing

Expanding D-PLEX Globally: MAA Submitted and Validated by the EMA and European Commercialization Rights to D-PLEX Regained

"PolyPid 2030" Growth Strategy Unveiled, Introducing PD01B, a New Kynatrix(TM)-Based Product Candidate for the Treatment of Diabetic Foot Infections

$30 Million Received from Azurity

Conference Call Scheduled for Today at 8:30 AM ET

PETACH TIKVA, Israel, Nov. 11, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2026.

Recent Corporate Highlights:

D-PLEX Under U.S. Food and Drug Administration ("FDA") Priority Review; PolyPid and Azurity Preparing for Potential U.S. Launch:

   -- The FDA is reviewing the New Drug Application ("NDA") for D-PLEX for the 
      prevention of surgical site infections ("SSIs") in patients undergoing 
      colorectal surgery under Priority Review, with a Prescription Drug User 
      Fee Act ("PDUFA") goal date of November 28, 2026. Labeling discussions 
      with the FDA are underway, and all scheduled FDA interactions are on 
      track and aligned with the PDUFA goal date. 
 
   -- Subject to approval, PolyPid and Azurity Pharmaceuticals ("Azurity") are 
      preparing for the U.S. commercial launch of D-PLEX in early 2027. Azurity 
      is building its U.S. commercial organization, with an existing hospital 
      footprint that reaches more than 1,700 leading U.S. hospitals and 
      academic centers. 
 
   -- A New Technology Add-on Payment ("NTAP") application for D-PLEX has been 
      submitted to the Centers for Medicare & Medicaid Services ("CMS"), with a 
      decision expected in August 2027. If granted, NTAP would provide 
      additional hospital reimbursement for D-PLEX in the inpatient setting. 
 
   -- PolyPid has received a total of $30 million in upfront and near-term 
      milestone payments from Azurity, comprising $15 million upon signing of 
      the agreement in July 2026 and an additional $15 million milestone 
      payment following FDA acceptance of the NDA, received subsequent to 
      September 30, 2026. PolyPid remains eligible for over $290 million in 
      additional regulatory, launch and sales-based milestone payments. In 
      addition, upon commercialization, PolyPid will receive a pre-negotiated 
      transfer price for each unit of D-PLEX it manufactures and supplies to 
      Azurity, as well as tiered royalties ranging from mid-teen to 
      mid-twenties percentages on sales in the U.S. and Canada. 

Expanding D-PLEX Globally:

   -- On September 14, 2026, PolyPid submitted its Marketing Authorization 
      Application ("MAA") for D-PLEX to the European Medicines Agency ("EMA") 
      under the Centralized Procedure, meeting its previously communicated 
      third quarter 2026 timeline. Subsequent to quarter end, the EMA validated 
      the MAA, initiating its formal review. A decision is expected in the 
      second half of 2027. 
 
   -- PolyPid and ADVANZ PHARMA mutually agreed to terminate their 2022 
      exclusive License, Distribution and Supply Agreement for D-PLEX in Europe, 
      and exclusive European commercialization rights to D-PLEX have reverted 
      to PolyPid. 
 
   -- The Company is in active discussions with potential commercial partners 
      in Europe. 

"PolyPid 2030" Strategy and Expanded Kynatrix(TM) Pipeline:

   -- Subsequent to quarter end, on October 28, 2026, PolyPid hosted its 
      "PolyPid 2030" virtual investor day and KOL event, outlining a long-term 
      growth strategy built on three levers: maximizing D-PLEX through the 
      Azurity partnership, including label expansion beyond colorectal surgery; 
      expanding D-PLEX into Europe and other territories through partnerships; 
      and building a Kynatrix-based pipeline. 
 
   -- Introduced PD01B, a new hyper-localized Kynatrix-based product candidate 
      for the treatment of moderate to severe diabetic foot infections 
      following wound debridement. PD01B is designed to deliver 
      high-concentration doxycycline in the wound for weeks and is expected to 
      be developed under its own NDA, separate from D-PLEX . PD01B leverages 
      the active ingredient, Kynatrix technology, manufacturing site and 
      processes, and preclinical and safety foundation established for D-PLEX . 
      PolyPid holds worldwide commercial rights to PD01B. 
 
   -- PolyPid's long-acting obesity program, PD03A, continues in early 
      preclinical development. 

"With our PDUFA goal date fast approaching, this is a defining moment for PolyPid," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "We have a committed partner in Azurity preparing to bring D-PLEX to surgeons and patients in the U.S., subject to approval, and we now hold full rights to D-PLEX in Europe. As D-PLEX moves toward commercialization, we are leveraging the Kynatrix technology to strengthen our pipeline. At our recent investor day, we presented how it can reach beyond surgical site infections, starting with PD01B in diabetic foot infections, a serious condition where systemic antibiotics often fall short. We are now focused on executing our PolyPid 2030 plan, and we look forward to sharing our progress."

Upcoming Expected Milestones:

   -- PDUFA goal date for the D-PLEX NDA of November 28, 2026. 
 
   -- Initiation of FDA communications on label expansion of D-PLEX into 
      broader abdominal surgery in the fourth quarter of 2026. 
 
   -- Potential U.S. commercial launch of D-PLEX by Azurity in early 2027. 
 
   -- New Drug Submission for D-PLEX in Canada in 2027. 
 
   -- CMS decision on NTAP for D-PLEX in August 2027. 
 
   -- EMA decision on the D-PLEX MAA in the second half of 2027. 
 
   -- PD01B pre-Investigational New Drug ("IND") meeting with the FDA and 
      first-in-human study, both expected in the second half of 2027. 

Financial Results for the Three Months Ended September 30, 2026

   -- Research and development expenses for the three months ended September 
      30, 2026, were $6.5 million, compared to $5.3 million in the same 
      three-month period of 2025. The increase was primarily due to the ongoing 
      NDA-related activities and continued commercial readiness preparation. 
 
   -- General and administrative expenses for the three months ended September 
      30, 2026, were $1.5 million, compared to $1.8 million for the same period 
      of 2025. The decrease was primarily due to the decrease of non-cash 
      expenses related to performance-based options following the positive 
      Phase 3 SHIELD II topline results, which triggered the vesting of those 
      options. 
 
   -- Marketing and business development expenses for the three months ended 
      September 30, 2026, were $0.4 million, compared to $0.4 million for the 
      same period of 2025. 
 
   -- Other income for the three months ended September 30, 2026, was $2.5 
      million, reflecting the recognition of previously deferred revenue 
      following the termination of the ADVANZ agreement on September 30, 2026. 
 
   -- For the three months ended September 30, 2026, the Company had a net loss 
      of $5.8 million, or $(0.24) per share, compared to a net loss of $7.5 
      million, or $(0.37) per share, in the three-month period ended September 
      30, 2025. 

Financial Results for the Nine Months Ended September 30, 2026

   -- Research and development expenses for the nine months ended September 30, 
      2026, were $18.4 million, compared to $17.6 million in the same 
      nine-month period of 2025. The increase was primarily due to the ongoing 
      NDA-related activities and continued commercial readiness preparation. 
 
   -- General and administrative expenses for the nine months ended September 
      30, 2026, were $4.4 million, compared to $5.4 million for the same period 
      of 2025. The decrease was primarily due to the decrease of non-cash 
      performance-based options vesting expenses. 
 
   -- Marketing and business development expenses for the nine months ended 
      September 30, 2026, were $1.3 million, compared to $1.4 million for the 
      same period of 2025. 
 
   -- Other income for the nine months ended September 30, 2026, was $2.5 
      million, as described above. 
 
   -- For the nine months ended September 30, 2026, the Company had a net loss 
      of $21.3 million, or $(0.94) per share, compared to a net loss of $25.7 
      million, or $(1.72) per share, in the nine-month period ended September 
      30, 2025. 

Balance Sheet Highlights

   -- As of September 30, 2026, the Company had cash, cash equivalents and 
      short-term deposits of $15.5 million, compared to $12.9 million on 
      December 31, 2025. Following the end of the quarter, the Company received 
      an additional $15 million milestone payment from its U.S. partner, 
      Azurity, following the FDA's acceptance of the D-PLEX NDA, further 
      strengthening its balance sheet. 
 
   -- The Company believes that its current cash position, together with its 
      expected proceeds from its commercialization agreement with Azurity, as 
      well as future potential proceeds, will be sufficient to fund operations 
      into 2028 and through several significant upcoming potential milestones. 

Conference Call Dial-In & Webcast Information:

 
Date:             Wednesday, November 11, 2026 
Time:             8:30 AM Eastern Time 
Conference Call:  https://register-conf.media-server.com/register/B 
                  Ia693ec3496b1413b8682b952b2ff9e10 
Webcast:          https://edge.media-server.com/mmc/p/rsj3o3mw 
 

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid's lead product, D-PLEX , successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the FDA's review of the D-PLEX NDA, including the PDUFA goal date, the outcome and timing of such review, the Company's ongoing labeling discussions with the FDA, and the potential approval of D-PLEX ; the anticipated timing of a potential U.S. commercial launch of D-PLEX by Azurity and Azurity's launch preparations; potential reimbursement for D-PLEX , including the anticipated timing of a CMS decision on NTAP; the timing, receipt and amount of regulatory, launch and sales-based milestone payments, transfer price payments and royalties under the Company's agreement with Azurity; the potential label expansion of D-PLEX , including the planned initiation of communications with the FDA and the anticipated timing of potential label expansion; the EMA's review of the MAA for D-PLEX , the anticipated timing of a decision and a potential EU launch; the Company's plans for the commercialization of D-PLEX in Europe and other territories, including potential partnerships; the planned New Drug Submission for D-PLEX in Canada; the Company's "PolyPid 2030" growth strategy; the design, development plan, regulatory pathway and anticipated timing of a pre-IND meeting and first-in-human study for PD01B, and its potential benefits; the Company's plans to advance Kynatrix technology through additional pipeline programs, including its long-acting obesity program, PD03A, and the anticipated development and potential applications of such programs; the Company's belief that its current cash position, together with its expected proceeds from its commercialization agreement with Azurity, as well as future potential proceeds, will be sufficient to fund operations into 2028 and through several significant upcoming potential milestones; and the therapeutic and commercial potential of D-PLEX . Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission, including, but not limited to, the risks detailed in the Company's Annual Report on Form 20-F filed on February 25, 2026. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Company Contact:

PolyPid Ltd.

Ori Warshavsky

908-858-5995

IR@Polypid.com

Investor Relations Contact:

Arx Investor Relations

North American Equities Desk

polypid@arxhq.com

 
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) 
-------------------------------------------------------------------------- 
U.S. dollars in thousands 
                                          September 30,     December 31, 
                                              2026              2025 
                                         ---------------  ---------------- 
 
      ASSETS 
 
CURRENT ASSETS: 
   Cash and cash equivalents              $        5,414   $       6,402 
   Restricted deposits                               201             193 
   Short-term deposits                            10,085           6,531 
   Accounts receivable                            15,000               - 
   Pre-launch inventories                          1,567           1,106 
   Prepaid expenses and other current 
    assets                                           901             995 
                                             -----------      ---------- 
 
Total current assets                              33,168          15,227 
---------------------------------------      -----------      ---------- 
 
NON-CURRENT ASSETS: 
   Property and equipment, net                     4,553           5,094 
   Operating lease right-of-use assets             1,181           1,675 
   Long-term deposits                                318             311 
   Other long-term asset                             900               - 
                                             -----------      ---------- 
 
Total non-current assets                           6,952           7,080 
---------------------------------------      -----------      ---------- 
 
Total assets                              $       40,120   $      22,307 
---------------------------------------      ===========      ========== 
 
 
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) 
-------------------------------------------------------------------------- 
U.S. dollars in thousands (except share and per share 
 data) 
                                          September 30,     December 31, 
                                              2026              2025 
                                         ---------------  ---------------- 
 
      LIABILITIES AND SHAREHOLDERS' 
      EQUITY 
 
CURRENT LIABILITIES: 
   Trade payables                         $       1,573    $      2,856 
   Accrued expenses and other current 
    liabilities                                   2,981           2,734 
   Current maturities of long-term debt               -             988 
   Current maturities of operating 
    lease liabilities                             1,030           1,161 
                                             ----------       --------- 
 
Total current liabilities                         5,584           7,739 
---------------------------------------      ----------       --------- 
 
NON-CURRENT LIABILITIES: 
   Deferred revenues                             30,000           2,548 
   Long-term operating lease 
    liabilities                                     227             647 
   Long-term other liabilities                      408             400 
                                             ----------       --------- 
 
Total non-current liabilities                    30,635           3,595 
---------------------------------------      ----------       --------- 
 
COMMITMENTS AND CONTINGENT LIABILITIES 
SHAREHOLDERS' EQUITY: 
Ordinary shares, no par value - 
Authorized: 107,800,000 shares at 
September 30, 2026 and December 31, 
2025; Issued and outstanding: 
21,125,704 and 18,204,002 shares at 
September 30, 2026 and December 31, 
2025, respectively                                    -               - 
   Additional paid-in capital                   326,732         312,473 
   Accumulated deficit                         (322,831)       (301,500) 
                                             ----------       --------- 
 
Total shareholders' equity                        3,901          10,973 
---------------------------------------      ----------       --------- 
 
Total liabilities and shareholders' 
 equity                                   $      40,120    $     22,307 
---------------------------------------      ==========       ========= 
 
 
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 
 (UNAUDITED) 
--------------------------------------------------------------------------- 
U.S. dollars in thousands (except share and per share 
 data) 
                        Nine Months Ended           Three Months Ended 
                          September 30,               September 30, 
                    -------------------------  ---------------------------- 
                        2026         2025          2026           2025 
                    ------------  -----------  ------------  -------------- 
 
 
Operating 
expenses: 
   Research and 
    development     $    18,404   $    17,589  $     6,523   $     5,257 
   Marketing and 
    business 
    development           1,291         1,421          418           432 
   General and 
    administrative        4,384         5,427        1,529         1,766 
   Other income          (2,548)            -       (2,548)            - 
                     ----------    ----------   ----------    ---------- 
 
Operating loss           21,531        24,437        5,922         7,455 
Loss on 
 extinguishment of 
 debt                         -           512            -             - 
Financial expense 
 (income), net             (208)          661         (170)          (26) 
                     ----------    ----------   ----------    ---------- 
 
Loss before income 
 tax                     21,323        25,610        5,752         7,429 
Income tax 
 expenses                     8            86            2            22 
                     ----------    ----------   ----------    ---------- 
 
Net loss            $    21,331   $    25,696  $     5,754   $     7,451 
                     ==========    ==========   ==========    ========== 
 
Basic and diluted 
 loss per ordinary 
 share              $      0.94   $      1.72  $      0.24   $      0.37 
                     ==========    ==========   ==========    ========== 
 
Weighted average 
 number of 
 ordinary shares 
 used in computing 
 basic and diluted 
 loss per share      22,751,434    14,920,521   23,677,711    20,054,071 
                     ==========    ==========   ==========    ========== 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment